On April 22, Neuboron Medical Group, a leading global Accelerator-based Boron Neutron Capture Therapy total solution provider, and Xiamen Humanity Hospital collaborated to co-host the Xiamen BNCT Technology Forum 2023 at the BNCT center in XHH.
El Efecto Mandela consiste en una situación en la que hay diversas personas que creen que ocurrió un evento, pero no fue de esa manera, siendo un fenómeno que puede observarse en acontecimientos históricos, películas, series de televisión, entre ot …
Diagnostic company SphingoTec has been successfully re-certified according to ISO 13485 and received its first IVDR certificate for its IVD product sphingotest® penKid®.
The first quarter of the year saw continued strong growth, record gross margin and the launching of our first IVDR-approved product.
Devyser Diagnostics AB publishes quarterly report for the period January to March 2023 Read More »
Theranexus and the Beyond Batten Disease Foundation, have announced receipt of approval from the Food and Drug Administration for the design and primary and secondary endpoints of the pivotal Phase III trial for Batten disease CLN3, at a meeting with the Division of Rare Diseases and Medical Genetics held in mid-April.
Spago Nanomedical Towards clinic with Tumorad®
Spago Nanomedical Interim Report January-March 2023 Read More »
Biophytis SA announced that it has filed for a pre-submission meeting request with the European Medicine Agency to discuss filing for conditional Marketing Authorisation in Europe for Sarconeos in the treatment of severe form of COVID-19.
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities General Regulation, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as at May 1, 2023.
Number of shares and voting rights of Innate Pharma as of May 1, 2023 Read More »
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041.
Ochre Bio, an innovator in chronic liver disease medicine development, has announced its participation in upcoming investor and industry conferences, sharing expert perspectives and insights across liver disease and RNA therapeutics, building and scaling startups, and the future of medicine.
Ochre Bio to Participate in Upcoming Global Industry Conferences – May 09, 2023 Read More »
